Shots: The approval is based on KEYNOTE-057 (NCT02625961) study involves assessing of Keytruda (200 mg, q3w) in 96 patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in […]readmore
Tags : BCG-Unresponsive